|
|
Дата |
|---|
| 16.11.2026 |
| 13.11.2026 |
| 12.11.2026 |
| 11.11.2026 |
| 10.11.2026 |
| 09.11.2026 |
| 06.11.2026 |
| 05.11.2026 |
| 04.11.2026 |
| 03.11.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
13.69
|
|
|
|
|
|
|
|
13.69
|
13.69
|
13.69
|
13.69
|
|
|
1 163.65
|
1.00
|
|
|
|
|
|
|
14.58
|
|
|
|
|
|
|
|
|
|
|
14.58
|
|
|
|
|
|
|
|
14.25
|
14.25
|
14.58
|
14.58
|
|
|
4 341.00
|
2.00
|
|
|
|
10.26
|
10.26
|
13.15
|
12.80
|
|
|
6 843.50
|
4.00
|
|
|
|
|
|
|
11.64
|
|
|
|
|
|
|
|
12.00
|
12.00
|
12.00
|
12.00
|
|
|
480.00
|
1.00
|
|
|
|
|
|
|
13.06
|
|
|
|
|
|
|
|
13.06
|
13.06
|
13.06
|
13.06
|
|
|
861.96
|
1.00
|
Iambic Therapeutics, Inc. is a technology and clinical-stage life sciences company. Its molecular superintelligence platform integrates proprietary AI technologies with automated, scalable chemistry and biology experimentation. Its pipeline of drug candidates is developed using a molecular superintelligence platform. IAM1363, is a HER2 inhibitor that is in a Phase I/Ib clinical trial in subjects with HER2-altered solid tumors. The Company's additional programs, IAM217 (KIF18A inhibitor) and IAM-C1 (dual CDK2/4 inhibitor), are in preclinical development. IAM1363 is an oral, selective, pan-mutant, and brain-penetrant small molecule inhibitor that selectively targets HER2 and HER2 mutants, while sparing EGFR.
Amplification and mutations of HER2 drive a wide range of human cancers. IAM-C1 is a small-molecule inhibitor with a differentiated selectivity profile, designed to specifically target CDK2 and CDK4, two cell-cycle kinases that are frequently dysregulated in various cancers.
Показать все Скрыть